model of T-NHL in which a subset of T cells are engineered to express a cancerous protein that drives human T-NHL. These T cells proliferate continuously, leading to cancer. By using a genetic screen to introduce random mutations into the animals' T cells, the researchers found that interfering with PD-1 expression reliably induced massive proliferation of cancerous T cells. Moreover, in humans, mutations in the gene encoding PD-1 correlated with moreaggressive lymphoma.
This makes sense, because in T-NHL, the T cells are the tumour cells. Inactivation of T cells through PD-1 signalling does not protect the tumour -as would normally be the case -but rather suppresses proliferation of cancerous cells (Fig. 1b) . Thus, T-cell tumours such as T-NHL can benefit from the loss of PD-1 signalling. The source of the PD-1 ligand that activates PD-1 signalling in T-NHL could be any of a range of immune-cell types, or even the tumour cells themselves.
Finally, Wartewig et al. showed that treatment of the T-NHL model mice with a PD-1 antibody, as would be done for patients, led to rapid and lethal proliferation of the cancerous T cells. This highlights a dangerous possible side effect of using anti-PD-1 treatment in the clinic.
Anti-PD-1 treatment significantly improves survival rates associated with therapies for several types of solid tumour, including skin 4 and lung 5 cancers. It has also proved beneficial in blood cancers that are not T-cell derived 6 . But Wartewig and colleagues' work indicates that the treatment might actually worsen certain cancers. The authors suggest that, in humans who have PD-1 mutations, the use of PI3K inhibitors might be preferable to treatment with an anti-PD-1 antibody.
How should these findings be interpreted in the context of human cancer? First, it is necessary to consider that the T-cell population is diverse and contains several subsets of cells that have distinct functions and characteristics. A study 7 recently showed that PD-1 blockade activates specific T-cell subsets, rather than having a general effect on the entire population. This suggests that anti-PD-1 treatment might aggravate disease progression only if it induces proliferation of the specific T-cell subtype that yielded the cancer.
Second, PD-1 inhibition also affects other types of cell in the cancer milieu -for instance, immune cells known as macrophages that 'swallow' damaged cells, disposing of them through a process called phagocytosis. In a tumour setting, macrophages do not necessarily eliminate tumour cells; instead they can promote tumour growth. PD-1 is expressed on tumour-associated macrophages, and PD-1 signalling reduces phagocytosis 8 . Moreover, anti-PD-1 treatment restores phagocytosis in tumour-related macrophages and reduces tumour burden 8 . These data indicate that macrophages should be considered when analysing the effects of PD-1 blockade on cancer.
PD-1 blockade has previously been used in patients with T-cell lymphoma without yielding disastrous results 9 , highlighting the need to uncover the other mechanisms at play. Perhaps PD-1 blockade activates other types of cell that combat the tumour, or maybe it did not affect the cancerous T-cell subtype in these patients.
In the era of immune-based cancer therapies, Wartewig and colleagues' study raises an important point: drugs that stimulate T-cell activity should be carefully studied to ensure that their use doesn't trigger the proliferation of cancerous cells. A better grasp of the detailed mechanisms that underlie the effects of PD-1 blockade in T-cell-derived tumours is still needed. An understanding of which cells are specifically affected by PD-1 blockade, and what abnormal traits they acquire following treatment, would enable an assessment of the efficacy of using PD-1 blockade to treat specific types of T-NHL. This knowledge should improve the treatments offered in the clinic and reduce possible harmful side effects. ■ This article was published online on 15 November 2017.
In Retrospect

Quantum-teleportation experiments turn 20
In 1997, it was demonstrated that quantum states can be teleported from one location to a distant one. The discovery had huge consequences for the development of quantum communication and computing.
N I C O L A S G I S I N
W ho has never dreamed of undergoing teleportation? Especially when stuck in a traffic jam. To get disembodied here and reconstituted at a distant location sounds both marvellous and impossible. But is it really impossible? True, a body made out of matter cannot merely disappear here and reappear there without travelling the intervening distance. But an object is not just matter, it is also structure -substance and form, as Aristotle taught us long ago; particles and quantum states, as physicists would say today. Twenty years ago, Boschi et al. 1 and Bouwmeester et al. 2 used this idea to perform the first quantum-teleportation experiments, which led to major advances in quantuminformation science.
In 1993, a group of theoretical physicists 3 were discussing two subjects that were highly discredited at the time: entanglement and non-locality. Entanglement is a phenomenon in which two or more quantum particles share a common state, such that each particle cannot be described independently. Non-locality refers to the observation that spatially separated quantum particles behave in ways that defy our intuition about space and time. Suddenly, the theorists realized that a pair of entangled particles could be used to teleport a quantum state from one location to a distant one, even if the sender does not know the quantum state or the location of the receiver (Fig. 1) . During the teleportation process, matter at the sender's location would lose its structure, and unstructured matter at the receiver's location would acquire this structure. The quantum state would therefore disappear from the sender and reappear at the receiver. Note that this process does not create a copy of the quantum state because the state at the sender is destroyed -as required by a principle known as the quantum no-cloning theorem 4, 5 . In addition to the two entangled particles, the teleportation process would require a tiny amount of classical (non-quantum) information to be broadcast by the sender. In the usual case of a quantum state that is parameterized by two ordinary (real) numbers,
